Business Wire

SES

23.2.2021 08:52:12 CET | Business Wire | Press release

Share
SES Networks Transforms Cruise Market Again as Leading Cruise Companies Choose O3b mPOWER for Enhanced Connected Guest Experiences

Four of the top five major cruise companies have entered into long-term strategic framework agreements, with the majority extending through 2026 and beyond, for services delivered over SES's next-generation O3b mPOWER communications system, SES announced today. These agreements will enable enhanced connectivity experiences onboard their current fleets as well as ships planned as part of their extensive new-build programmes, and result in a backlog of over EUR 220 million.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222006011/en/

The advanced connectivity solutions delivered by SES will elevate guest connectivity to provide an ultimate digital immersive experience, enabling more wearable technologies and unlocking more personalised services. This reflects a major trend across the cruise industry and the priorities of leading cruise companies as they prepare to resume sailing. The latest contracts with SES Networks reinforce that SES is the clear market leader within the cruise connectivity segment, having secured significant market share of the cruise companies' mega new-build ship programmes. Dating back to 2019, SES has provided over 13 Gbps – or 2/3 of the total capacity delivered to the cruise industry.

O3b mPOWER is SES's global terabit-level scalable constellation that will operate in medium earth orbit (MEO) – or 8,000km away from earth. Based on the proven success of SES's current O3b system, the new system provides an unprecedented increase in flexibility and throughput and is capable of continuously delivering multiple gigabits per second to a single ship anywhere on earth during seasonal peaks and in areas of high density. O3b mPOWER’s advanced technical features, which include a “follow-the-ship” capability, allow for maximum efficiency in delivering the highest throughput available today wherever a ship is travelling. The new O3b mPOWER system provides the ideal combination of global coverage and low-latency, high-throughput performance for the cruise market, ensuring seamless immersive wi-fi and connectivity experiences.

With satellites scheduled to launch in late 2021 and service beginning in 2022, the high-performance connectivity delivered by O3b mPOWER will help the cruise industry to:

  • Leverage a highly-resilient global network to deliver an always-on fibre-like connectivity experience
  • Deliver seamless and secured access to cloud-based platforms and applications for shipboard productivity, passenger communications and entertainment
  • Dynamically optimise the required bandwidth and increased connectivity to any ship wherever and whenever it may be
  • Deliver fastest internet speeds at sea, resulting in truly immersive guest experiences
  • Achieve cruise liners’ operational efficiencies by enabling real-time condition monitoring and other connected Operational Technology (OT)

“COVID-19 has been challenging for the cruise industry. At the same time, it has also enabled major players in the industry to re-strategise on their plans for the future and focus on technology-driven innovation and how they can outdo themselves in creating the best holiday experience for passengers, and high-performance connectivity is central to those strategies. We are pleased to be co-creating these advanced solutions along with our customers and ensuring we can meet their future needs,” said JP Hemingway, CEO of SES Networks.

Follow us on:

https://twitter.com/SES_Satellites
https://www.facebook.com/SES.Satellites
https://www.youtube.com/ses
https://www.linkedin.com/company/ses/
https://www.instagram.com/ses_satellites/

Read our Blogs >
Visit the Media Gallery >

About SES

SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/SES.Satellites/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye